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Abstract
The HIV-1 genome enters cells inside a shell comprised of capsid (CA) protein. Variation in CA sequence alters HIV-1
infectivity and escape from host restriction factors. However, apart from the Cyclophilin A-binding loop, CA has no known
interfaces with which to interact with cellular cofactors. Here we describe a novel protein-protein interface in the N-terminal
domain of HIV-1 CA, determined by X-ray crystallography, which mediates both viral restriction and host cofactor
dependence. The interface is highly conserved across lentiviruses and is accessible in the context of a hexameric lattice.
Mutation of the interface prevents binding to and restriction by CPSF6-358, a truncated cytosolic form of the RNA
processing factor, cleavage and polyadenylation specific factor 6 (CPSF6). Furthermore, mutations that prevent CPSF6
binding also relieve dependence on nuclear entry cofactors TNPO3 and RanBP2. These results suggest that the HIV-1 capsid
mediates direct host cofactor interactions to facilitate viral infection.
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Introduction
The HIV-1 genome enters target cells encapsulated in a
fullerene capsid cone composed of capsid (CA) protein. The role of
the capsid in early events of the HIV-1 replication cycle is not
known, nor is it clear exactly how long the capsid remains
associated with the infectious particle, or where the capsid
disassembles. Early biochemical studies led to the view that the
capsid is an inert shell, required during particle assembly and
target cell entry, whereupon it rapidly falls apart (‘uncoats’) to
permit reverse transcription [1,2]. However, recent data suggest
that uncoating may occur later than previously thought, either
during transport of the reverse transcribing virus to the nucleus, or
once the reverse transcribing virus has docked at the nuclear pore
[3,4,5,6,7]. This accommodates the possibility that the capsid may
facilitate transit of the core towards the nucleus by interacting with
the cell’s cytoskeletal transport system [5]. An intact capsid would
also be expected to maintain a high stoichiometry of reverse
transcriptase enzyme to viral template, which is necessary for
overcoming the rate limiting steps in reverse transcription [4,8].
Like all lentiviruses, HIV-1 is able to infect non-dividing cells,
which requires the exploitation of active host cell nuclear import
processes [9]. CA mutations have been identified that specifically
affect nuclear entry in non-dividing cells [10,11,12], suggesting a
link between CA and nuclear import. However, apart from the
Cyclophilin (Cyp)-binding loop, there are no known interfaces
through which the CA can interact with host cell cofactors. CA
mutations outside of the Cyp-binding loop have been suggested to
exert their effect by altering capsid stability or particle assembly.
For example, it has been proposed that CA mutations that
decrease the ability of HIV-1 to enter the nucleus (Q63A/Q67A)
or infect non-dividing cells (A92E, G94D or T54A/N57A) do so
by causing the capsid to uncoat faster or slower than wild type
[10,11,12,13]. However, many CA mutations that give clear
infectivity defects are located on an exposed surface in the CA
hexamer structure (Figure 1, [14,15]) and therefore seem unlikely
to purely affect capsid stability.
Recent genome-wide screens have implicated a number of
nuclear import components as HIV-1 cofactors, including the
nuclear pore proteins RanBP2 (also called NUP358) and NUP153
and the karyopherin TNPO3 [16,17,18]. In each case, there is
evidence that the requirement for these import cofactors map to
CA [6,19,20,21,22,23,24,25]. Of particular interest, a single CA
mutation (N74D) has been shown to affect the sensitivity of HIV-1
to depletion of RanBP2, Nup153 and TNPO3 [6,19]. Mutation
N74D arose spontaneously during passage of HIV-1 in cells
expressing CPSF6-358, an artificially truncated version of cleavage
and polyadenylation specific factor 6 (CPSF6, also known as CF
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Im) that perturbs HIV-1 nuclear entry [19]. CPSF6 is a pre-
mRNA processing protein that dynamically shuttles between the
nucleus and the cytoplasm [26] and contains a C-terminal nuclear-
targeting arginine/serine-rich (RS-) domain [27,28] of the type
bound by TNPO3 [29,30]. CPSF6 lacking this RS-domain is no
longer confined to the nucleus but is also found in the cytoplasm
[28]. CPSF6-358 (which is truncated at position 358 and therefore
lacks the C-terminal RS-domain) was also found to be cytoplasmic
and restricted HIV-1 before nuclear entry [19]. It is therefore
significant that the HIV-1 CA N74D mutation not only allows
escape from CPSF6-358 restriction but also results in the loss of
viral dependence on several cofactors involved in nuclear entry
(RanBP2, Nup153 and TNPO3).
Here we show that CPSF6 binds specifically to a novel protein-
protein interface on the N-terminal domain of HIV-1 CA. We
show that this interface is structurally and functionally conserved
across lentiviruses from different genera and is accessible in the
context of an intact CA hexamer. We propose that CPSF6
interacts with incoming capsid during the post-entry stages before
uncoating. Structure-guided mutagenesis of this interface reveals
that CA residues that mediate CPSF6 binding also mediate
dependence on TNPO3 and RanBP2. Finally, addition of an
ectopic nuclear localization signal (NLS) to CPSF6-358 recovers its
nuclear localization and restores HIV-1 infectivity, suggesting that
the functional outcome of CPSF6 interaction with HIV-1 depends
on whether CPSF6 is trafficking into the nucleus or remaining in
the cytosol. Together, our data reveals that HIV-1 CA possesses a
previously undescribed, conserved protein-protein interface that
dictates cofactor dependence. Furthermore, it suggests that HIV-1
uses CA to interact directly with host cofactors and exploit cellular
nuclear import pathways.
Results
CPSF6 binds diverse lentiviral CAs
To test our hypothesis that CPSF6 interacts directly with the
HIV-1 CA we used a combination of biophysical, structural and
cellular infection approaches. Expression of soluble and correctly
folded full-length CPSF6 protein was not possible for technical
reasons. However, it has recently been shown that CPSF6 residues
301–358 are sufficient for restriction in a TRIM-fusion assay and
that conservation of residues 313–327 is necessary for full activity
[31]. We therefore synthesised a peptide corresponding to this
putative HIV-1-interacting region (CPSF6313–327) and tested
binding to recombinant HIV-1 CA N-terminal domain (CAN)
by isothermal titration calorimetry (ITC). We found that CPSF6
residues 313–327 were sufficient for direct binding to HIV-1 CAN
(Figure 2A) with low affinity (362 mM). Next, we tested binding of
CPSF6313–327 to HIV-1 CA mutant N74D, which escapes CPSF6-
358 restriction. This single mutation all but abolished binding to
CPSF6313–327 (Kd.5 mM) (Figure 2B). This suggests that CPSF6
binding to HIV-1 CA is specific and that N74D allows escape from
CPSF6-358 restriction by preventing CA interaction with CPSF6-
358. To determine whether CPSF6 binding is conserved across
diverse lentiviruses, we measured the interaction between
CPSF6313–327 and CA
Ns from HIV-2, SIVmac and FIV. All
three lentiviral CANs bound to CPSF6313–327, with an affinity of
219–350 mM (Figure 2C). Binding of CPSF6313–327 to HIV-2
and SIVmac agreed with published data showing that these viruses
are restricted by CPSF6-358 [19]. Binding of CPSF6313–327 to FIV
CAN was unexpected, given that FIV, like HIV-1 N74D, is
insensitive to CPSF6-358 restriction [19]. The reason for this
discrepancy is unclear, however it has previously been shown that
N74D replicates with wild-type efficiency in HeLa cells whereas it
does not replicate appreciably in macrophages, suggesting that
Figure 1. Exposed CA mutations affecting HIV-1 infectivity. Location of CA mutations that are solvent-exposed in the hexameric CA structure
and which are found to result in decreased HIV-1 infectivity [14]. CA mutations are labeled and represented as red spheres. The CA hexamer structure
was derived from pdb: 3H47 [15] by generating symmetry-related copies in PyMOL. Left: view looking down onto the hexamer, right: view from the
side, with CypA-binding loops at the top.
doi:10.1371/journal.ppat.1002896.g001
Author Summary
In order to infect a host cell, HIV-1 must interact with and
exploit cellular cofactors. Mutations within capsid, the
protein shell that surrounds the virus, have been shown to
affect virus usage of these cofactors and susceptibility to
host antiviral proteins. However, with the exception of the
Cyclophilin A-binding loop, there is no defined protein
interface on the capsid that mediates interactions with
cellular proteins. Here, we describe the identification of a
conserved interface on HIV-1 capsid that binds the host
protein CPSF6 and determines viral dependence on
nuclear transport cofactors. This data illustrates how
host-virus interactions allow HIV-1 to hitch a ride into
the nucleus and reveals a potential new target for antiviral
drugs.
CPSF6 Defines a Conserved HIV-1 Capsid Interface
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CPSF6 may be required for HIV-1 replication in primary cells [6].
It is therefore possible that FIV similarly only requires CPSF6 to
replicate in primary cells. This would agree with growing data that
there are multiple nuclear entry pathways that may be redundant
in certain cell lines [6,19].
Crystal structure of HIV-1 CAN in complex with CPSF6313–327
To understand how CPSF6313–327 binds directly to HIV-1 CA
N,
we solved the crystal structure of the complex between HIV-1
CAN and CPSF6313–327 at 1.8 A˚ resolution (Figure 3). In the
complexed structure, CPSF6313–327 lies in a binding site compris-
ing a narrow channel formed on one side by helix 4 and on the
other by helices 3 and 5 and the helix 5/6 turn (Figure 3A).
Three discrete pockets in the centre of the channel are filled by
CPSF6 residues V314, L315 and F321 (Figure 3B). The channel
is closed at one end around residue Q63 and extends the length of
helix 4, until the beginning of the CypA-binding loop at V86
where it opens into solvent. The interface, as defined by CPSF6, is
bordered by CA residues 53, 56–57, 66–67, 70, 73–74, 105, 107,
109 and 130 (Figure 3C). CPSF6313–327 itself does not possess any
secondary structure but forms a relatively compact loop due to
intramolecular interactions centering on the Q319 side chain,
which hydrogen bonds to the amide nitrogen of F316 and the
carbonyl oxygens of V314 and Q323, pinning the two halves of
the peptide together (Figure 3D). Additional constraining
intramolecular interactions are made between the peptide oxygen
of F316 and the amide nitrogen of Q319, and between the peptide
oxygen of P320 and the amide nitrogen of Q323. Formation of
these interactions is facilitated by proline residues P317 and P320,
which introduce kinks into the backbone, and by glycine residues
G318 and G322, which confer backbone flexibility. The N and C
termini of CPSF6313–327 project directly out of the binding channel
(Figure 3E), suggesting that CPSF6313–327 is a protruding
structure within the full-length CPSF6 protein. This supports a
model in which CPSF6 residues 313–327 can access the CA
interface in the context of intact, full-length CPSF6.
Interactions in the HIV-1 CAN:CPSF6313–327 complex
CPSF6313–327 is highly hydrophobic, containing only two polar
residues (Q319 and Q323). Therefore, it makes a number of
hydrophobic interactions with CA, including via V314, L315 and
F321, which project into the channel at the centre of the binding
interface (Figure 3B). In addition to hydrophobic burial of
CPSF6 side chains, CPSF6 is also held in place by a number of
hydrogen bonds between side chains in HIV-1 CAN and the
backbone amide and carbonyl groups of CPSF6313–327, some of
Figure 2. CPSF6 binds diverse lentiviral capsids. Isothermal titration calorimetry (ITC) of CPSF6313–327 against CA
N domains of lentiviral capsids.
CPSF6313–327 binding to HIV-1 is specific (A), being abolished by CA mutation N74D (B). CPSF6313–327 also binds to diverse primate lentiviral capsids,
HIV-2, FIV and SIVmac (C). The stoichiometry (N), affinity (Kd), enthalpy (DH) and entropy (DS) of interaction are shown.
doi:10.1371/journal.ppat.1002896.g002
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Figure 3. Crystal structure of HIV-1 CAN in complex with CPSF6313–327. (A) Crystal structure of the HIV-1 CA
N:CPSF6313–327 complex. HIV-1
CAN is shown as cartoon representation and CPSF6 as sticks. Secondary structure elements in HIV-1 CAN are labeled. The electron density for the
CypA-binding loop was poor, so this region is represented by a dashed line. (B) Close-up view of the HIV-1 CAN:CPSF6313–327 interface, showing HIV-1
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which are water-mediated (Figure 4). Significantly, the side chain
of CA residue N74 makes a bifurcated hydrogen bond with the
main chain of L315 in CPSF6 (Figure 4B), which explains why
the N74D mutation resulted in loss of binding to CPSF6313–327
and escape from restriction by CPSF6-358 (Figure 2B and [19]).
Two water-mediated interactions are also made between the
backbone amide of V314 in CPSF6 and the main chain carbonyl
of N74, and between the backbone carbonyl of V314 and the side
chain of T107 (Figure 4B). CPSF6 makes two further interactions
with side chains from helix 4 in HIV-1 CAN: one between the
backbone nitrogen of G318 in CPSF6 and the CA Q67 side chain;
and the other between the peptide oxygen of Q319 in CPSF6 and
the CA K70 side chain (Figure 4C). CA N57 is another key
interaction residue for CPSF6 binding. Similar to CA N74, the
side-chain of N57 mediates a bifurcated hydrogen bond with the
backbone of F321 in CPSF6. This positions the benzyl side chain
of F321 for hydrophobic burial beneath the aliphatic side chain of
K70. The identification of CA N57 as an important residue for
CPSF6 binding is of interest, as mutation N57A impairs HIV-1
infection of nondividing cells [6]. Finally, several water-mediated
interactions are made between the backbone of G322 and the side
chains of N53 and Y130 and the main chain carbonyls of A105
and S109 (Figure 4D).
It is also worth noting the similarity between the location of the
CPSF6-binding interface and exposed CA mutations that have
been shown to affect infectivity (Figure 1). Many of the side
chains that are directly involved in CPSF6 binding (N57, Q67,
K70 and N74) were found to reduce HIV-1 infectivity in a
comprehensive alanine-scan of CAN [14] (Figure 4 and
Figure 5B and C). Furthermore, alanine-scan mutants that
map to the CPSF6 binding site are distinct in that their reduced
infectivity is not fully explained by structural or assembly defects.
Mutants Q63A/Q67A and N74A have 5–35 fold decreased
infectivity but normal levels of particle production and no
assembly defects [14]. Similarly, while mutants T54A/N57A and
K70A have fewer conical capsids, this was a minor defect (,4-fold
with respect to wild type HIV-1) compared to their effect on
infectivity (which was reduced by 20–80 fold) [14,32]. This lack of
correspondence between magnitude of structural defect and loss of
infection supports the conclusion that CPSF6 defines an interface
in which residues have a role in mediating protein interaction
necessary for optimal infection.
To address the accessibility of the CA:CPSF6 interface in the
context of the hexameric CA, we superposed our HIV-1
CAN:CPSF6313–327 complex structure onto the recently solved
structure of the HIV-1 CA hexamer (pdb: 3H47 [15]) (Figure 5).
The monomers of the hexamer are arranged radially from a centre
comprised of the packed N-terminal CA domains. The CPSF6-
binding interface is found on the outside edge of the hexamer,
where it is exposed to solvent and highly accessible for protein-
protein interaction (Figure 5A). The CPSF6-binding interface is
not involved in intra-hexamer or inter-hexamer interactions, the
latter of which occur exclusively between C-terminal CA domains
and build up the capsid lattice found in assembled virions
(Figure 5D). This suggests that CPSF6 binding does not require
the dissociation of subunits from the assembled capsid lattice. This
suggests that binding of CPSF6-358 to the CPSF6 interface on
capsid does not in and of itself restrict virus replication, for
example by directly affecting capsid stability and uncoating, but
rather competitively inhibits recruitment of endogenous CPSF6
and/or other cofactors necessary for productive nuclear import
and integration.
Mutation of the CPSF6-binding interface alters nuclear
entry cofactor dependence
To confirm that disruption of the CPSF6:CA interaction
impacts on virus replication, we mutated residue F321 in
CPSF6-358. The aromatic side chain of F321 forms extensive
hydrophobic interactions with CA, suggesting that it may be
essential for CPSF6:CA binding. We found that CPSF6-358
F321N was unable to restrict HIV-1, demonstrating that F321 is a
key residue for restriction of virus (Figure 6A and B). Next, we
investigated how loss of CPSF6:CA interaction alters known post-
entry cofactor dependencies. Mutation N74D is located at the
centre of the CPSF6-binding interface and abolishes binding of
CPSF6313–327 to CA. N74D also results in loss of dependence on
TNPO3, RanBP2 and Nup153, suggesting that the CPSF6-
binding interface may be involved in HIV-1 nuclear entry
[6,19,31]. To test this, we investigated whether there is a
correlation between mutation of CPSF6-binding interface resi-
dues, binding to CPSF6313–327, and viral dependence on nuclear
entry cofactors TNPO3 and RanBP2. Using our structure, we
designed CA mutations with the aim of specifically knocking out
CPSF6 binding. Five residues were selected for mutation (N57,
Q67, K70, N74 and T107), on the basis that (1) they bind CPSF6
via their side chain and not their main chain and (2) are not
obviously involved in maintaining CA structure. With the
exception of N74D [19], all residues were mutated to alanine in
accordance with previously published mutations [14]. We also
made an additional M66F mutation in order to occlude the
hydrophobic pocket filled by CPSF6 residue F321. Modelling of
this mutant on to our structure suggested that the only F66
rotamer that would permit normal HIV-1 folding would be one
that resulted in a steric clash with F321. We tested the effect of
these mutations on in vitro affinity to CPSF6313–327 (Figure 6C)
and the sensitivity of VSV-G pseudotyped HIV-1 to CPSF6-358
restriction and TNPO3 and RanBP2 depletion (Figure 6D). All
of the mutants showed reduced CPSF6313–327 affinity and CPSF6-
358 restriction, confirming that the mutations had acted to impair
CPSF6 binding. Strikingly, all of the mutations also resulted in
either the loss (N57A and N74D) or reduction (Q67A, K70A and
T107A) of dependence on TNPO3 and RanBP2, a phenotype
previously only shown for N74D and N57A [6,19].
Although all CA mutations tested were found to reduce both the
affinity of CA for CPSF6313–327 and the ability of CPSF6-358 to
restrict, a direct correlation between the magnitude of the two was
not observed. For instance, M66F reduced the affinity of CA to
CPSF6313–327 by 7-fold but only recovered infection in the
presence of CPSF6-358 by 3-fold. One possibility for this
difference may be that the mutation has a reduced effect on
binding in the context of hexameric or intact capsid. Indeed, in the
hexamer model, helix 4 (where M66 is located) packs against helix
8 leading to differences in the orientation of side-chains around
M66, such as Q63, with respect to the N-terminal capsid domain
CAN as surface representation. The three CPSF6 residues that fill the centre of the channel in HIV-1 are indicated. (C) The CPSF6-binding interface on
HIV-1 CAN. Residues involved in binding to CPSF6313–327 are labeled and shown in green. (D) Intramolecular interactions in CPSF6313–327. Residues
involved in intramolecular hydrogen bonding interactions are labeled and the interactions shown as dashed lines. The sequence of CPSF6313–327 is
shown for reference. (E) Stereo figure showing overview of the HIV-1 CAN:CPSF6313–327 interaction. The N- and C-termini of CPSF6313–327 (labeled)
project out of the binding channel in HIV-1 CAN.
doi:10.1371/journal.ppat.1002896.g003
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structure (Figure S1). Thus, although we predicted a rotamer
conformation for M66F that would occlude binding in the N-
terminal domain, rotamer occupancy may differ in the virion.
Mutations Q67A and K70A abolished sensitivity to CPSF6-358
whilst only showing a minimal effect on binding to CPSF6313–327
(Figure 6C and D). This may be illustrative of the fact that CA
mutations can affect both the stability of the capsid and the affinity
of interactions at the protein-protein interface. Therefore, the
effect of a capsid mutation on one process, such as uncoating, may
mask the effect of the same mutation on another process, such as
CPSF6-358 restriction, if the mutation leads to uncoating before
binding of CPSF6-358 occurs. In support of this, Q67A is a
mutant that is known to give rise to an unstable core [13,14].
Other examples of this phenomenon exist; for instance, the
unstable capsid mutant P38A is poorly restricted by TRIM5a
inside cells [33]. Similarly, PF-3450074 shows significantly
diminished inhibition of the unstable capsid mutant E45A, even
though this mutation has no effect on affinity of the drug for HIV-
1 particles [34]. In this respect, N74D is a particularly useful
mutant as it has near wild type infectivity levels, but a dramatic
reduction in affinity to CPSF6313–327 and restriction by CPSF6-
358 and the best correlation between the two. Importantly, the
direct correlation observed between escape from CPSF6-358
restriction and the lack of sensitivity to TNPO3 and RanBP2
Figure 4. Interactions in the HIV-1 CAN:CPSF6313–327 complex. (A–D) Detailed views of the HIV-1 CA
N:CPSF6313–327 interface. HIV-1 CA
N is
shown as grey cartoon, HIV-1 residues that bind CPSF6 are in green and CPSF6313–327 in yellow. Water molecules involved in water-mediated
interactions in the complex are shown as cyan spheres. (A) Overview of the HIV-1 CAN:CPSF6313–327 interface, showing all interacting residues and
intermolecular hydrogen-bonding interactions. Views of the close-ups shown in (B), (C) and (D) are indicated. (B–D) HIV-1 CAN a-helices are labeled
to aid orientation. Interacting residues are labeled (CPSF6 in normal font; HIV-1 in italics).
doi:10.1371/journal.ppat.1002896.g004
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depletion support a link between the CPSF6-binding interface in
CA and the utilization of specific nuclear entry pathway
components by HIV-1.
To provide further evidence that the CPSF6 interface is
important we investigated its conservation in HIV-1 and other
primate lentiviruses. Physiologically relevant protein-protein
interfaces are more conserved than non-interacting surfaces [35].
Sequence mapping of ,100 unique CAN sequences onto the
complexed structure showed that the CPSF6-binding interface is
highly conserved within HIV-1 CA (Figure 7A) suggesting that it
is a functionally important interface required for efficient HIV-1
infection. Alignment of the CAN sequences of other primate
lentiviruses reveals that the CA residues in HIV-1 that interact
with CPSF6 are also highly conserved in both HIV-2 and SIVmac
Figure 5. The CPSF6-binding interface is accessible and highly conserved in HIV-1 virions. (A) Model of CPSF6313–327 binding to HIV-1 CA
hexamer. The hexamer structure was derived from pdb: 3H47 [15] by generating symmetry-related copies in PyMOL. The model was composed by
superposition of CAN chains from HIV-1 CAN:CPSF6313–327 on the hexamer using secondary structure matching. HIV-1 CA helices are shown as
cylinders and CPSF6313–327 as spheres. Left: top view, right: side view. N-terminal and C-terminal CA domains (NTD and CTD) are labeled. (B) Close-up
of boxed region in (A). CAs are shown as cartoons and CPSF6313–327 as sticks. The region between CTD positions 175 and 188 was disordered and so
is represented by a dashed line. (C) Same view as in (B), showing exposed CA mutations (labelled and shown as red spheres) that result in decreased
HIV-1 infectivity [14] (see Figure 1). (D) Model of CPSF6313–327 binding at a hexamer-hexamer interface. Neighbouring hexamers were derived from
pdb: 3H47 by generating extended symmetry-related copies in PyMOL. HIV-1 CAN:CPSF6313–327 was superposed on the hexamer using secondary
structure matching. The model shows that CPSF6313–327 binding is likely to be accommodated at neighbouring CTD-mediated hexamer-hexamer
junctions.
doi:10.1371/journal.ppat.1002896.g005
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Figure 6. The CPSF6-binding interface determines HIV-1 nuclear entry requirements. (A–B) CPSF6 residue F321 is critical for interaction
with HIV-1 CAN. (A) HeLa cells expressing empty vector (white bar), HA-tagged CPSF6-358 (black bar) or CPSF6-358 bearing mutation F321N (striped
bar) were infected with GFP-encoding VSV-G pseudotyped HIV-1 vector. F321N abolished restriction by CPSF6-358, confirming the importance of this
residue in the HIV-1 CAN:CPSF6 interaction. (B) Western blot to show CPSF6-358 and CPSF6-358 F321N expression levels, with actin as loading control.
(C) ITC of CPSF6313–327 against mutant HIV-1 CA
Ns. All mutations at the CPSF6-binding interface resulted in reduced affinity to CPSF6313–327. The
stoichiometry (N), affinity (Kd), enthalpy (DH) and entropy (DS) of interaction are shown. (D) Titres of VSV-G pseudotyped GFP-encoding HIV-1 vectors
bearing wild type or mutant CA on HeLa cells expressing empty vector (EV), CPSF6-358, control knockdown cells (shC) and cells depleted for TNPO3
CPSF6 Defines a Conserved HIV-1 Capsid Interface
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(Figure 7B). The two HIV-1 mutations with the greatest effect on
both CPSF6 binding and restriction are N57A and N74D. To
determine if these residues are functionally conserved, we
introduced the equivalent mutations (N56A and N73D) into
HIV-2 and SIVmac. As can be seen, N56A and N73D potently
reverse CPSF6-358 restriction of both viruses (Figure 7C). This
data suggests that the CPSF6 binding interface is highly conserved
in HIV-1, HIV-2 and SIVmac.
(shTNPO3) or RanBP2 (shRanBP2). The data are representative of two independent experiments, each using three different virus doses. Mutation of
HIV-1 CAN residues involved in binding to CPSF6 resulted in the loss of dependence on TNPO3 and RanBP2, suggesting a link between CPSF6 binding
and normal nuclear import of HIV-1. (E) Western blot to show knockdown of TNPO3 and RanBP2, with cyclophilin A (CypA) as loading control.
doi:10.1371/journal.ppat.1002896.g006
Figure 7. The CPSF6 interface is conserved in HIV-1, HIV-2, SIVmac CAN. (A) The CPSF6-binding interface is highly conserved within HIV-1
viruses. The ConSurf Server [42,43] was used to map ,100 unique HIV-1 CAN sequences onto the HIV-1 CAN:CPSF6313–327 structure. HIV-1 CAN is
shown as surface representation and CPSF6313–327 as yellow sticks. The level of conservation at each position in CA
N is shown by the colour; dark
blue =most conserved, red = least conserved. Residues at the CPSF6-binding interface are among the most highly conserved of all, suggesting that
this is a functionally important interface. The figure was generated using the PyMOL script output by ConSurf, with conservation grades replacing the
B-factor column. (B) Sequence alignment of HIV-1, HIV-2, SIVmac CAN. (C) Titres of VSV-G pseudotyped GFP-encoding HIV-2 and SIVmac vectors
bearing wild type or mutant CA on HeLa cells expressing empty vector (EV) or CPSF6-358.
doi:10.1371/journal.ppat.1002896.g007
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Addition of an ectopic NLS to CPSF6-358 rescues CPSF6
nuclear localization and HIV-1 infection
CPSF6 is known to shuttle in and out of the nucleus [26] and
contains a C-terminal nuclear-targeting RS-domain [27,28] of the
type bound by TNPO3 [29,30]. We therefore investigated
whether the link between dependence on CPSF6, TNPO3 and
nuclear pore proteins is because binding of CPSF6 to HIV-1
facilitates nuclear entry. This hypothesis is suggested by the fact
that deletion of the nuclear-targeting domain of CPSF6 results in a
truncated cytosolic form (CPSF6-358) that reduces viral titre
[19,28]. Over-expressed cytosolic CPSF6-358 might act as a
dominant negative, preventing the use of endogenous CPSF6 by
HIV-1. We hypothesised that retargeting truncated CPSF6 to the
nucleus by attaching a different NLS motif might prevent
restriction and loss of titre. To test this, we determined the
infectivity of HIV-1 in HeLa cells exogenously expressing full
length CPSF6 (CPSF6-FL), the truncated form of CPSF6 (CPSF6-
358) and HeLa cells expressing CPSF6-358 with the SV40 NLS
sequence ‘PKKKRKVG’ at the C-terminus (CPSF6-358-NLS),
and compared the subcellular localization of CPSF6 inside these
cells. Whilst CPSF6-358 localized to both the cytosol and the
nucleus, CPSF6-FL and CPSF6-358-NLS were entirely nuclear
(Figure S2A). Furthermore, we observed that HIV-1 titre was
reduced 6.3-fold in cells expressing CPSF6-358, whereas efficient
infection was observed in cells expressing CPSF6-FL or CPSF6-
358-NLS (Figure S2B and C). The recovery of efficient infection
upon restoration of CPSF6 nuclear transport is consistent with a
model in which CPSF6 is a cofactor for HIV-1 nuclear import.
This result by itself does not rule out the possibility that CPSF6,
when expressed in the cytosol, serendipitously binds to and inhibits
HIV-1. CPSF6 may only inhibit HIV-1 if aberrantly localized in
the cytosol, for instance in cells depleted of TNPO3. However,
knocking out interaction with CPSF6 through a single point-
mutation (N74D) results in a virus that loses dependence on
TNPO3 and RanBP2 and that cannot replicate in macrophages,
consistent with the hypothesis that CPSF6 is a cofactor for primate
lentiviruses [6].
CPSF6-CAN structure reveals antiviral drug mechanism
Several drugs have been identified that directly bind to HIV-1
CA [36,37,38]. In each case they are thought to inhibit viral
replication by altering the stability of the capsid. Intriguingly, we
observe that the most recently described drug, PF-3450074, binds
within the CPSF6-binding interface [38]. Even more remarkably,
one of the phenyl rings of the drug superposes almost exactly with
the phenyl ring of CPSF6 residue F321, a critical residue for
CPSF6-CA interaction (Figure 8A and B). Based on these data,
we hypothesised that PF-3450074 may be a competitive inhibitor
of a cellular cofactor, most likely CPSF6. To test this, we
investigated whether PF-3450074 competes with CPSF6313–327 for
CA binding and whether the drug occupies the same interface as
CPSF6313–327, as defined by the CA
N mutants used in this study.
The synthesis for PF-3450074 has not been published nor was it
possible to obtain the compound from Pfizer, therefore we
performed a 4-step synthesis (as described in Methods) from
which we obtained .400 mg of material at .95% purity. Similar
to published data, we found that the drug bound to wild type HIV-
1 CAN with an affinity of 5 mM (Figure 8C). PF-3450074 was also
able to completely inhibit binding of CPSF6313–327 to CA
(Figure 8D). The antiviral activity of PF-3450074 is therefore
consistent with the hypothesis that CPSF6 is an important HIV-1
cofactor.
Binding experiments with different capsid mutants revealed that
mutations N57A or K70A were sufficient to abolish PF-3450074
binding completely (Figure 8C). This is in agreement with the
PF-3450074:HIV-1 CAN crystal structure, which shows that
residues N57 and K70 form direct hydrogen bonds with the drug
(Figure 8B). However, mutation of other key CPSF6 interface
residues had little effect on drug binding; N74D and M66F
reduced the affinity by 2- and 3-fold respectively, while Q67A had
no effect despite Q67 forming a (weak) water-mediated hydrogen
bond with the drug (Figure 8B and C). The reduced effect of the
M66F mutant on the drug with respect to CPSF6313–327 (3-fold
versus 7-fold) may be because the peptide places greater
constraints on the flexibility of the binding pocket than the drug.
Thus, M66F may be better at accommodating a small drug than a
large peptide. One mutation, T107A, resulted in an increased
affinity to the drug (Kd = 1 mM), possibly due to the removal of a
slight steric repulsion between one of the aromatic moieties in PF-
3450074 and the T107 side chain. These data show that PF-
3450074 occupies only one pocket within a larger protein interface
bound by CPSF6. Consequently, it may be possible to develop
more effective high-affinity drugs by addressing this entire
interface as a drug target, either by compound or fragment
screening or rational drug design.
Discussion
Although there is extensive experimental evidence that the
HIV-1 capsid is more than a packaging device to carry viral
protein and nucleic acid into the cell, no interaction interfaces
other than the Cyp-binding loop have been identified on its
surface. For instance, despite considerable effort the structural
interface between capsid and the restriction factor TRIM5a
remains incompletely characterized. Here we have described the
identification of a conserved interface within the N-terminal CA
domain and shown that interface mutations alter HIV-1 interac-
tion with CPSF6 and cofactors RanBP2 and TNPO3. Previously,
CA mutation N74D has been shown to escape CPSF6-358
restriction whilst simultaneously relieving dependence on nuclear
transport factors such as TNPO3 and a functional nuclear pore
[6,19]. We have shown that CA residue N74 makes an essential
interaction with CPSF6, both by solving the crystal structure of a
CPSF6:CA complex and by showing that mutation N74D
abolishes binding to CPSF6. Furthermore, mutation N74D results
in a virus that has no defect in infectious titre on immortalized cells
but that cannot replicate in macrophages [6]. This suggests that
CPSF6 may be an important cofactor in HIV infection. Further
evidence in support of CPSF6 as a cofactor is that addition of an
ectopic NLS to CPSF6-358 restores both nuclear localization of
CPSF6-358 and HIV-1 infectivity. However, we cannot rule out
that this might be due to a reduction in the concentration of
cytosolic CPSF6-358 that would otherwise prevent functional
interaction of endogenous CPSF6 with CA.
CPSF6 is transported into the nucleus and contains an RS-
domain, which is known to interact with karyopherins like TNPO3
[29,30]. A compelling model for the role of the CPSF6 interface in
HIV-1 replication is therefore that binding to CPSF6 facilitates
active nuclear transport. Such a model would explain why
mutation N74D results in concomitant loss of both CPSF6
interaction and dependence on TNPO3 and RanBP2; if the virus
cannot bind CPSF6 then it cannot recruit TNPO3 to pass through
the nuclear pore. We have further substantiated the connection
between CPSF6 binding and TNPO3 and RanBP2 dependence
through structure-guided mutagenesis of the CPSF6-binding
interface. This has identified five CA mutations that have the
same pleiotropic effects as N74D (N57A, M66F, Q67A, K70A and
T107A). If CPSF6 is an HIV-1 cofactor then it would allow
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seemingly conflicting data that report different viral targets for
TNPO3 requirement and interaction to be resolved: the require-
ment for TNPO3 maps to CA [23], but TNPO3 has been found to
bind integrase (IN) and not CA [17]. Recruitment of TNPO3 to
CA-bound CPSF6 could explain why CA determines TNPO3
requirement, while also accommodating a role for IN as the direct
viral binding partner of TNPO3. In this context, it is important to
note that the interaction of CPSF6313–327 with CA, whilst specific,
occurs with weak affinity. The affinity of the full-length protein for
assembled virions is presumably significantly higher. The low
affinity we have measured may be augmented by avidity, as there
are many potential CPSF6 binding sites per virion, and CPSF6 is
known to be part of a heterotetrameric protein complex together
with CFIm25 [39]. Alternatively, the addition of other proteins
such as TNPO3 may stabilize the CPSF6:CA complex. For
instance, it is possible that a larger complex comprising CPSF6,
CA, TNPO3 and/or IN exists inside the cell and future structural
investigation of this possibility is likely to be highly informative.
Recent findings suggest that HIV-1 may utilize flexible nuclear
import pathways [6,19,20]. Redundancy in HIV-1 infection is
conceptually appealing as it provides a mechanism for viral escape
from host immunity and effective zoonosis. For instance, the RS-
domain of CPSF6 may be recognised by more than one
karyopherin. Likewise, other RS-domain containing proteins
may use the CPSF6 interface. This may be helpful for the virus
but it adds to the complexity of investigating cofactor dependence.
In this respect, interface mutations may be particularly useful to
unpick which factors operate in a shared pathway and which are
redundant. The seeming interdependency of multiple host factors
on a single capsid mutant, N74, suggests that they operate in a
single pathway, which the virus utilizes for efficient infection.
Given the host factors involved, this single pathway most likely
involves nuclear import of the virus.
Irrespective of the role of CPSF6 itself, the conservation and
location of the CPSF6 interface, together with the effects of
mutations that disrupt it, suggest that it plays an important role in
HIV-1 infection. The importance of the CPSF6 interface in HIV-1
infection is supported by the fact that random drug screening
recently resulted in the discovery of a drug, PF-3450074, that
inhibits infection and mimics very closely the core F321 residue of
CPSF6 (Figure 7A) [38]. The CPSF6-binding interface on HIV-1
CA possesses several important attributes that make it an ideal
antiviral drug target, in that it is highly conserved, functionally
important and druggable. Since PF-3450074 occupies only a
subset of the entire CPSF6-binding site, it is unlikely to be as
effective a drug as one that inhibits the entire interface. Our
complexed HIV-1 CAN:CPSF6313–327 crystal structure provides a
molecular delineation of the CPSF6 interface that may be useful in
the development of antiviral therapeutics.
Materials and Methods
Protein expression and purification
HIV-1 and HIV-2 CAN were expressed in BL21 (DE3) E. coli
cells and purified as described (price et al). SIVmac and FIV CAN
were expressed with an N-terminal His tag in BL21 (DE3) E. coli
cells and purified by capture on Ni-NTA resin (Qiagen) followed
by gel filtration. All HIV-1 CAN mutants were purified as per the
wild type protein.
Isothermal titration calorimetry (ITC)
Proteins were prepared by dialysis against a buffer containing
50 mM potassium phosphate (pH 7.4), 100 mM NaCl and 1 mM
DTT. The chemically synthesized CPSF6313–327 peptide (Designer
Bioscience) was dissolved in the same buffer. ITC experiments
were conducted on a MicroCal ITC-200 as described [38], with
CPSF6313–327 (10 mM) in the syringe and CA
N (600 mM) in the
cell, unless otherwise indicated. Drug PF-3450074 was synthesized
in-house and binding to CAN proteins carried out with protein
(200 mM) in the syringe and drug (30 mM) in the cell. Data were
analyzed using Origin data analysis software (MicroCal).
Crystallization, data collection, structure determination
and refinement
Crystals of HIV-1 CAN:CPSF6313–327 grew at 17uC in sitting
drops. Protein/peptide solution (0.37 mM HIV-1 CAN and 4 mM
CPSF6313–327 in 20 mM HEPES pH 7, 50 mM NaCl, 1 mM
DTT) was mixed with reservoir solution (20% w/v PEG 3350,
0.2 M potassium phosphate dibasic) in a 1:1 mix, producing
0.55 mm60.15 mm60.05 mm crystals within one week. Crystals
were flash-frozen in liquid nitrogen and data collected on an in-
house Mar-345 detector to a resolution of 1.8 A˚. Crystal data
collection and refinement statistics are provided in Table S1. The
dataset was processed using the CCP4 program suite [40]. Data
were indexed and scaled in MOSFLM and SCALA, respectively.
The structure was determined by molecular replacement in
PHASER using HIV-1 CAN (pdb: 2GON) as a model. Structural
figures were prepared using PyMOL (MacPyMOL Molecular
Graphics System, 2009, DeLano Scientific LLC).
Cells and viruses
HeLa cells were transfected with EXN-based expression
plasmids containing HA-tagged CPSF6 constructs and transduced
cells were selected with 1 mg/ml G418 (Gibco). Gene expression
was confirmed by western blot using a-HA monoclonal antibody
16B12 (Covance). HeLa cells stably depleted for TNPO3 or
NUP358 were made using short hairpin sequences expressed from
MLV vector pSIREN RetroQ (Clontech) as described [6] and
depletion confirmed using mouse TNPO3 antibody ab54353
(Abcam) and a NUP358 antibody kindly given by Frauke
Melchior. VSV-G pseudotyped GFP-encoding lentiviral vectors
based on HIV-1 NL4.3 were prepared in HEK 293T cells, as
described [41].
Infection assays
Cells were seeded in 6-well plates at 16105 cells/well and
inoculated with GFP-reporter virus in the presence of 5 mg/ml
polybrene. The virus dose was selected so as to infect ,30% of
unmodified cells and the percentage of GFP-positive cells
enumerated 48 h later by flow cytometry. Unless otherwise
indicated, experiments were performed in triplicate and one
Figure 8. Drug PF-3450074 binds to part of the CPSF6-binding interface in HIV-1 CAN. (A) Superposition of HIV-1 CAN:PF-3450074
structure (pdb: 2XDE) [38] on HIV-1 CAN:CPSF6313–327 using secondary structure matching of the HIV-1 CA
N domains. Drug PF-3450074 is shown in
cyan, CPSF6313–327 in yellow. The three CPSF6 residues that fill the centre of the channel in HIV-1 are indicated. One of the phenyl rings in PF-3450074
superposes almost exactly with the phenyl ring of F321 in CPSF6313–327. (B) Crystal structure of HIV-1 CA
N:PF-3450074 (pdb: 2XDE) showing residues
involved in binding to CPSF6 (green sticks). The yellow sphere represents a water molecule involved in a water-mediated interaction in the complex.
(C) ITC of PF-3450074 against wild type and mutant HIV-1 CANs. (D) Titration of 1 mM CPSF6313–327 into 80 mM HIV-1 CA
N was carried out in the
absence or presence of 100 mM PF-3450074 (‘control’ and ‘+ drug’ respectively). PF-3450074 completely inhibits binding of CPSF6313–327 to HIV-1 CAN.
doi:10.1371/journal.ppat.1002896.g008
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representative experiment is shown in each case. Titers are plotted
as infectious units per ng of reverse transcriptase activity 6
standard deviation.
Immunofluorescence
Cells were plated on glass coverslips, washed with PBS and fixed
with 4% PFA in PBS before being permeabilized with 0.5%
Triton in PBS for 10 min at room temperature, washed with PBS
and then blocked with 5% BSA in PBS containing 0.1% Tween
(PBST) for 1 h at room temperature. Cells were incubated for 1 h
with the first antibody (a-HA 16B12) at 1:250 dilution, washed
three times with PBST and then incubated for 1 h with the
secondary antibody (Alexa-488 conjugated anti-mouse IgG
(Invitrogen)) at 1:400 dilution. Coverslips were mounted onto
glass slides using Vectashield mounting medium with DAPI
(Vector Labs) and imaged using a Zeiss 780 confocal microscope
equipped with a 636/1.4 NA Plan-Apochromat oil-immersion
objective. Images were taken under identical conditions to aid
comparison. Images were prepared using ImageJ (NIH).
Synthesis of PF-3450074
PF-3450074 was obtained in a 4-step synthesis as described in
the Supplementary Methods (Text S1). Small molecule LC-MS
was carried out using the Agilent system using a Phenomenex
Jupiter 15062 mm, C18, 5 mm column. Variable wavelengths
were used and MS acquisitions were carried out in positive and
negative ion modes. Kieselgel 60 F-254 commercial plates were
used for analytical TLC, UV light and/or potassium permanga-
nate stain was used to follow the course of the reaction. Flash
chromatography (FC) was performed with silica gel grade 9385
pore size 60 A˚, 230–400 mesh. The structure of each compound
was confirmed by 1H & 13C NMR (400 & 100 MHz, Bruker
spectrometer). Mass spectra were obtained on an Agilent 1200
series LC-MS system.
Accession codes
Protein Data Bank: Coordinates for HIV-1 CAN:CPSF6313–327
have been deposited (PDB ID code 4b4n).
Supporting Information
Figure S1 Superposition of the HIV-1 CAN:CPSF6313–327
complex on HIV-1 CA hexamer. The CPSF6 peptide is
shown in yellow, the N-terminal capsid domain in cyan and the N-
terminal and C-terminal domains of hexamer are shown in gray
and pink respectively. The side chains of M66 and Q63 are
indicated. The hexamer structure was derived from pdb 3H47
[15]. The monomer and hexamer structures display different loop
conformations between helices 4 and 5, in proximity to M66.
(EPS)
Figure S2 Addition of ectopic NLS rescues CPSF6-358
nuclear localization and HIV-1 infection. (A) Typical
confocal microscopy images of HeLa cells expressing HA-tagged
full-length CPSF6 (CPSF6-FL), CPSF6-358 (CPSF6-358) and
CPSF6-358 with an additional C-terminal SV40 NLS (CPSF6-
358-NLS). Addition of the SV40 NLS onto CPSF6-358 rescued
CPSF6 nuclear localization. Scale bars, 10 mm. (B) Titres of VSV-
G pseudotyped GFP-encoding HIV-1 vector on HeLa cells
expressing empty vector (EV), or the indicated CPSF6 constructs.
Addition of the SV40 NLS onto CPSF6-358 rescued HIV-1
infection. (C) HA-tagged CPSF6 expression levels as determined
by western blot, with actin as loading control.
(EPS)
Table S1 Crystallographic data collection and refine-
ment statistics.
(PDF)
Text S1 Supplementary methods.
(PDF)
Acknowledgments
We thank Frauke Melchior for the anti RanBP2 antibody. The content of
this publication does not necessarily reflect the views or policies of the
Department of Health and Human Services, nor does mention of trade
names, commercial products, or organizations imply endorsement by the
U.S. Government.
Author Contributions
Conceived and designed the experiments: AJP AJF TS GJT LCJ.
Performed the experiments: AJP AJF TS TE. Analyzed the data: AJP
AJF TS GJT LCJ. Contributed reagents/materials/analysis tools: TE KL
VNK JWC. Wrote the paper: AJP AJF VNK GJT LCJ.
References
1. Fassati A, Goff SP (2001) Characterization of intracellular reverse transcription
complexes of human immunodeficiency virus type 1. J Virol 75: 3626–3635.
2. Miller MD, Farnet CM, Bushman FD (1997) Human immunodeficiency virus
type 1 preintegration complexes: studies of organization and composition. J Virol
71: 5382–5390.
3. Hulme AE, Perez O, Hope TJ (2011) Complementary assays reveal a
relationship between HIV-1 uncoating and reverse transcription. Proc Natl
Acad Sci U S A 108: 9975–80.
4. Arhel NJ, Souquere-Besse S, Munier S, Souque P, Guadagnini S, et al. (2007)
HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex
at the nuclear pore. EMBO J 26: 3025–3037.
5. Arhel N (2010) Revisiting HIV-1 uncoating. Retrovirology 7: 96.
6. Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, et al. (2011) HIV-1
Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integra-
tion Targeting and Replication Efficiency. PLoS Pathog 7: e1002439.
7. Arfi V, Lienard J, Nguyen XN, Berger G, Rigal D, et al. (2009) Characterization
of the behavior of functional viral genomes during the early steps of human
immunodeficiency virus type 1 infection. J Virol 83: 7524–7535.
8. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, et al. (1994) HIV-1
reverse transcription. A termination step at the center of the genome. J Mol Biol
241: 651–662.
9. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, et al.
(1992) Active nuclear import of human immunodeficiency virus type 1
preintegration complexes. Proc Natl Acad Sci U S A 89: 6580–6584.
10. Qi M, Yang R, Aiken C (2008) Cyclophilin A-dependent restriction of human
immunodeficiency virus type 1 capsid mutants for infection of nondividing cells.
J Virol 82: 12001–12008.
11. Yamashita M, Perez O, Hope TJ, Emerman M (2007) Evidence for direct involvement
of the capsid protein in HIV infection of nondividing cells. PLoS Pathog 3: 1502–1510.
12. Ylinen LM, Schaller T, Price A, Fletcher AJ, Noursadeghi M, et al. (2009)
Cyclophilin A levels dictate infection efficiency of human immunodeficiency
virus type 1 capsid escape mutants A92E and G94D. J Virol 83: 2044–2047.
13. Dismuke DJ, Aiken C (2006) Evidence for a functional link between uncoating of
the human immunodeficiency virus type 1 core and nuclear import of the viral
preintegration complex. J Virol 80: 3712–3720.
14. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI (2003) Functional
surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77:
5439–5450.
15. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, et al. (2009) X-ray
structures of the hexameric building block of the HIV capsid. Cell 137: 1282–1292.
16. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008)
Identification of host proteins required for HIV infection through a functional
genomic screen. Science 319: 921–926.
17. Christ F, Thys W, De Rijck J, Gijsbers R, Albanese A, et al. (2008) Transportin-
SR2 imports HIV into the nucleus. Curr Biol 18: 1192–1202.
18. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, et al. (2008) Global
analysis of host-pathogen interactions that regulate early-stage HIV-1 replica-
tion. Cell 135: 49–60.
CPSF6 Defines a Conserved HIV-1 Capsid Interface
PLOS Pathogens | www.plospathogens.org 13 August 2012 | Volume 8 | Issue 8 | e1002896
19. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, et al. (2010) Flexible use of
nuclear import pathways by HIV-1. Cell Host Microbe 7: 221–233.
20. Ocwieja KE, Brady TL, Ronen K, Huegel A, Roth SL, et al. (2011) HIV
Integration Targeting: A Pathway Involving Transportin-3 and the Nuclear Pore
Protein RanBP2. PLoS Pathog 7: e1001313.
21. Cribier A, Segeral E, Delelis O, Parissi V, Simon A, et al. (2011) Mutations
affecting interaction of integrase with TNPO3 do not prevent HIV-1 cDNA
nuclear import. Retrovirology 8: 104.
22. De Iaco A, Luban J (2011) Inhibition of HIV-1 infection by TNPO3 depletion is
determined by capsid and detectable after viral cDNA enters the nucleus.
Retrovirology 8: 98.
23. Krishnan L, Matreyek KA, Oztop I, Lee K, Tipper CH, et al. (2010) The
requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection
maps to human immunodeficiency virus type 1 capsid and not integrase. J Virol
84: 397–406.
24. Logue EC, Taylor KT, Goff PH, Landau NR (2011) The cargo-binding domain
of transportin 3 is required for lentivirus nuclear import. J Virol 85: 12950–
12961.
25. Zhou L, Sokolskaja E, Jolly C, James W, Cowley SA, et al. (2011) Transportin 3
Promotes a Nuclear Maturation Step Required for Efficient HIV-1 Integration.
PLoS Pathog 7: e1002194.
26. Ruepp MD, Aringhieri C, Vivarelli S, Cardinale S, Paro S, et al. (2009)
Mammalian pre-mRNA 39 end processing factor CF I m 68 functions in mRNA
export. Mol Biol Cell 20: 5211–5223.
27. Ruegsegger U, Blank D, Keller W (1998) Human pre-mRNA cleavage factor Im
is related to spliceosomal SR proteins and can be reconstituted in vitro from
recombinant subunits. Mol Cell 1: 243–253.
28. Dettwiler S, Aringhieri C, Cardinale S, Keller W, Barabino SM (2004) Distinct
sequence motifs within the 68-kDa subunit of cleavage factor Im mediate RNA
binding, protein-protein interactions, and subcellular localization. J Biol Chem
279: 35788–35797.
29. Kataoka N, Bachorik JL, Dreyfuss G (1999) Transportin-SR, a nuclear import
receptor for SR proteins. J Cell Biol 145: 1145–1152.
30. Lai MC, Lin RI, Huang SY, Tsai CW, Tarn WY (2000) A human importin-beta
family protein, transportin-SR2, interacts with the phosphorylated RS domain of
SR proteins. J Biol Chem 275: 7950–7957.
31. Lee K, Mulky A, Yuen W, Martin TD, Meyerson NR, et al. (2012) HIV-1
Capsid Targeting Domain of Cleavage and Polyadenylation Specificity Factor 6.
J Virol 86: 3851–60.
32. Hatziioannou T, Cowan S, Von Schwedler UK, Sundquist WI, Bieniasz PD
(2004) Species-specific tropism determinants in the human immunodeficiency
virus type 1 capsid. J Virol 78: 6005–6012.
33. Shi J, Aiken C (2006) Saturation of TRIM5 alpha-mediated restriction of HIV-1
infection depends on the stability of the incoming viral capsid. Virology 350:
493–500.
34. Yang R, Shi J, Byeon IJ, Ahn J, Sheehan JH, et al. (2012) Second-site
suppressors of HIV-1 capsid mutations: restoration of intracellular activities
without correction of intrinsic capsid stability defects. Retrovirology 9: 30.
35. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol
Biol 280: 1–9.
36. Ternois F, Sticht J, Duquerroy S, Krausslich HG, Rey FA (2005) The HIV-1
capsid protein C-terminal domain in complex with a virus assembly inhibitor.
Nat Struct Mol Biol 12: 678–682.
37. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, et al. (2007) Structure of the
antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol
Biol 373: 355–366.
38. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, et al. (2010) HIV
capsid is a tractable target for small molecule therapeutic intervention. PLoS
Pathog 6: e1001220.
39. Yang Q, Coseno M, Gilmartin GM, Doublie S (2011) Crystal structure of a
human cleavage factor CFI(m)25/CFI(m)68/RNA complex provides an insight
into poly(A) site recognition and RNA looping. Structure 19: 368–377.
40. Collaborative Computational Project N (1994) The CCP4 suite: programs for
protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760–763.
41. Besnier C, Takeuchi Y, Towers G (2002) Restriction of lentivirus in monkeys.
Proc Natl Acad Sci U S A 99: 11920–11925.
42. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N (2010) ConSurf 2010:
calculating evolutionary conservation in sequence and structure of proteins and
nucleic acids. Nucleic Acids Res 38: W529–533.
43. Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, et al. (2005) ConSurf
2005: the projection of evolutionary conservation scores of residues on protein
structures. Nucleic Acids Res 33: W299–302.
CPSF6 Defines a Conserved HIV-1 Capsid Interface
PLOS Pathogens | www.plospathogens.org 14 August 2012 | Volume 8 | Issue 8 | e1002896
